Prosecution Insights
Last updated: November 20, 2026
Application No. 18/569,952

DUAL CURABLE SILICONE COMPOSITION

Final Rejection §103
Filed
Dec 13, 2023
Priority
Jun 22, 2021 — provisional 63/213,281 +1 more
Examiner
OLADAPO, TAIWO
Art Unit
1771
Tech Center
1700 — Chemical & Materials Engineering
Assignee
DuPont de Nemours Inc.
OA Round
2 (Final)
53%
Grant Probability
Moderate
3-4
OA Rounds
2m
Est. Remaining
65%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
630 granted / 1183 resolved
-11.7% vs TC avg
Moderate +12% lift
Without
With
+11.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
64 currently pending
Career history
1275
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
55.1%
+15.1% vs TC avg
§102
14.6%
-25.4% vs TC avg
§112
16.4%
-23.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1183 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The response dated 09/01/2026 was considered but was not found to be persuasive. Therefore, the previous rejections are maintained. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 1 – 7 are rejected under 35 U.S.C. 103 as being unpatentable over Ogawa et al. (WO 2020/090346 A1) In regard to claim 1, Ogawa teaches ultraviolet (UV) curable organosiloxane composition (title). The composition comprises A) an organosiloxane and/or an organopolysiloxane having at least two UV curable functional groups and B) a polysilsesquioxane (abstract). The component A:B are present at ratios of from 50-99 : 1-50, wherein A) can be 70% or more, and B) can be 60% or less and 7% or more, based on the amounts of components A and B [0059]. The organosiloxane can have a formula 4) wherein a is 0 or a positive number, b is 0 to 100, and c + d is a positive number, thus allowing d to be 0, and c to be 1 or more, and wherein each R is a UV curable functional group, or a monovalent hydrocarbyl group and which is analogous to the structure of formula 1 of the claim, and which provides limitations overlapping the claimed range [0040]. The UV functional group includes epoxy groups such as 3,4-epoxycyclohexylethyl and the monovalent hydrocarbyl group can be alkyl or aryl having 1 to 20 carbon atoms such as benzyl etc. [0030, 0031]. The polysilsesquioxane component B comprises polymerizable groups such as acrylic or methacrylic groups [0044]. In addition to components A and B, the composition can comprise a UV polymerization initiator such as photo radical polymerization initiator at amounts of from 0.01 to 5% in the composition such as benzophenone, acetophenone etc., and photocationic polymerization initiator at from 0.1 to 5% in the composition such as sulfonium and iodonium salts which provides the photo acid generator and/or thermal acid generator and the photo radical polymerization initiator and/or thermal radical polymerization initiator of the claim, respectively [0053 – 0057]. The structure and repeat units a, b, c, d are analogous and thus would intrinsically provide siloxane units in the claimed amounts. Also, since the R groups can be hydrocarbyl such as benzyl (i.e., C6 hydrocarbon) or UV curable functional groups such as epoxy-substituted organic groups, either can be present at from 0 to 100% as the R groups or their combinations at amounts of between 0 and 100% which would provide amounts overlapping the claimed ranges. Thus, the structure provides the component A1 of the claim. The composition may comprise silicone structures of a formula (3) wherein the groups R1 to R8 are hydrocarbyl such as benzyl (i.e., C6 hydrocarbon) or UV curable functional groups such as epoxy-substituted organic groups such as such as 3,4-epoxycyclohexylethyl, etc., which is analogous to A2 of the claims [0033 – 0035]. Thus, individual structures or combinations of structures providing A1 and/or A2 of the claims are obvious. Thus, the dual curable silicone composition of the claim is provided. In regard to claim 2, Ogawa teaches the composition which can comprise the components A1 and/or A2 of the claims as organosiloxane and/or an organopolysiloxane having at least two UV curable functional groups, and thus their combinations at equal amounts would be obvious. In regard to claims 3 – 6, Ogawa teaches the composition having the claimed ingredients as previously discussed. In regard to claim 7, Ogawa teaches the composition having the claimed ingredients and thus would be expected to have similar properties as claimed. Response to Arguments Applicant's arguments have been fully considered but they are not persuasive. Applicant argues that Ogawa teaches individual silicone compounds of the formula 3 or 4 but does not teach their mixtures. The argument is not persuasive. On the contrary, paragraph 0014 of Ogawa clearly teaches mixtures of the silicone compounds were suitable. Applicant argues that Ogawa also does not teach the combination of initiators of the claims. The argument is not persuasive. Again, Ogawa teaches combinations of photo radical polymerization initiator and thermal radical polymerization initiator as discussed in the rejections above. Applicant argues that the repeat units a, b, c, and d overlaps the claimed range and are so broad as to encompass many compounds. The argument is not persuasive. The claimed ranges are overlapped thus providing the claimed compounds. Applicant argues that the claimed composition demonstrates unexpectedly superior properties over the prior art. The argument is not persuasive. While the claims allow for much broader amounts of components A, B, C, D, the inventive examples require amounts that are either specific or very narrow which do not support the breadth of the claimed ranges nor demonstrate criticality of the claimed range. While the claims allow for much broader compounds meeting the limitations of A, B, C, D, the inventive examples require only two kinds of components A and B and only one specific compound for each of the component C or D which do not support the breadth of the claimed range. The results are not persuasive. Some of the comparative examples provide similar or equally superior performances as the inventive examples. Thus, the allegation of unexpectedly superior improvement is inconsistent over the prior art. Thus, applicant fails to provide inventive examples that are commensurate in scope with the claims for demonstrating unexpected results sufficient to rebut the case of obviousness. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TAIWO OLADAPO whose telephone number is (571)270-3723. The examiner can normally be reached 8-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Prem Singh can be reached at 571-272-6381. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TAIWO OLADAPO/Primary Examiner, Art Unit 1771
Read full office action

Prosecution Timeline

Dec 13, 2023
Application Filed
Jun 01, 2026
Non-Final Rejection mailed — §103
Sep 01, 2026
Response Filed
Nov 06, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799418
FUEL COMPOSITION FOR COMBUSTION
2y 9m to grant Granted Nov 17, 2026
Patent 12790560
LUBRICATING OIL COMPOSITIONS FOR HYDROGEN FUELED ENGINES FOR REDUCED PRE-IGNITION
1y 8m to grant Granted Nov 10, 2026
Patent 12781150
LUBRICATING OIL COMPOSITION
1y 10m to grant Granted Nov 03, 2026
Patent 12760235
OIL-IN-WATER EMULSIONS
3y 4m to grant Granted Oct 13, 2026
Patent 12760437
Self-Lubricating Coating, Fabrication Method, and Electrical Contact
2y 8m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
53%
Grant Probability
65%
With Interview (+11.9%)
3y 1m (~2m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1183 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month